Hi all -
Just did guardant360 - and results as above. I do not understand the relevance of the amplification of 0.4%
METS to bone and spine 2018 jan
ER/PR +ve HER2 -ve
Line 1. March-dec 2018 - arimidex - progression
Line 2. Dec 2018 ibrance /faslo/zometa
Have just had small progression of existing mets (more suv uptake on pet/ct scans )
In addition - MRI a month ago showed progression of epidural tumor in my T4-T6 spine.
They have now stopped ibrance and i completed radiation x10 to T4-T6 today.
Any similar stories from you as to options available for Line 3 treatment ?
I have not as yet discussed with oncology future options for 3rd line.
Any comments will be so appreciated!
Thank you - Jo